Ionis Pharmaceuticals (IONS) announced that the FDA has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals granted Breakthrough Therapy designation for olezarsen
- Arrowhead price target raised to $48 from $27 at Goldman Sachs
- Ionis Pharmaceuticals Completes $770M Convertible Notes Offering
- Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval
- Arrowhead price target raised to $45 from $29 at Morgan Stanley